DiaMedica Therapeutics Inc. Common Stock/$DMAC

1D1W1MYTD1Y5YMAX

About DiaMedica Therapeutics Inc. Common Stock

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Ticker
$DMAC
Sector
Health
Primary listing
NASDAQ
Employees
35
Headquarters
Minneapolis, United States
Website
www.diamedica.com

DMAC Metrics

BasicAdvanced
$369M
-
-$0.72
0.97
-

What the Analysts think about DMAC

Analyst ratings (Buy, Hold, Sell) for DiaMedica Therapeutics Inc. Common Stock stock.
Analyst projections of the future price of DiaMedica Therapeutics Inc. Common Stock stock.

Bulls say / Bears say

DM199 produced a mean 29.1 mmHg fall in systolic blood pressure and a 17.0 mmHg fall in diastolic pressure in the highest-dose pre-eclampsia cohorts, with systolic pressure staying below 160 mmHg for 24 hours. Both results were statistically significant, giving the programme a clear clinical signal to take into further Phase 2 work. (DiaMedica Therapeutics)
The ReMEDy2 Phase 2/3 stroke trial has passed 85% of the 200 patients needed for its pre-specified interim analysis, with about 70 sites active across North America, the UK and Europe. The interim readout is expected in the first quarter of 2027, creating a defined catalyst for the shares. (DiaMedica Therapeutics)
DiaMedica is advancing DM199 across pre-eclampsia, fetal growth restriction and acute ischaemic stroke rather than relying on one trial. It has completed enrolment in the first fetal-growth-restriction cohort and is expanding its pre-eclampsia work, giving positive data in one indication more chances to support the wider platform. (DiaMedica Therapeutics)
Stroke execution remains a risk: the company says ReMEDy2 has experienced slower-than-expected site activation and patient enrolment. The protocol also allows the interim review to stop the study for futility or increase the final sample to as many as 728 patients, which could extend both the timeline and cost. (StockTitan)
The cash cushion is shrinking while spending rises. Cash, cash equivalents and investments fell to $43.5 million from $59.9 million at the end of 2025, while six-month operating cash use increased to $17.2 million; the company says it will need substantial additional capital, creating future dilution risk. (DiaMedica Therapeutics, StockTitan)
The pre-eclampsia signal is still early and narrow: the headline result comes from only 15 participants in combined highest-dose cohorts, while the company has yet to present the full pharmacokinetic and pharmacodynamic dataset. A blood-pressure response in late-onset disease still needs to translate into durable maternal and infant outcomes in larger controlled studies. (DiaMedica Therapeutics, The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 20 Sept 2026.

DMAC Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

DMAC Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

DMAC News

AllArticlesVideos

DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences

Business Wire3 weeks ago

DiaMedica Therapeutics Q2 Earnings Call Highlights

MarketBeat1 month ago

DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Business Wire1 month ago

Funds containing DMAC

Funds
Fund name
Fund size
$DMAC weighting
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.